Medicover stock price target raised to SEK265 from SEK215 at Deutsche Bank

Deutsche Bank raised its price target for Medicover AB (MCOVB) to SEK265.00 from SEK215.00, citing approximately 20% upgrades to FY25-27 EPS estimates, strong organic growth, and better operating leverage, while maintaining a "Hold" rating. The bank noted that the stock price largely reflects current performance and indicated it would await new mid-term targets from management before reconsidering its investment stance.

Analysis

Deutsche Bank has materially increased its price target on Medicover AB (STO:MCOVB) to SEK265.00 from SEK215.00, underpinned by a substantial 20% upgrade to its FY25-27 earnings per share estimates. This revision, which aligns the bank's forecasts with consensus, is attributed to the company's sustained strong teens organic growth and better-than-anticipated operating leverage. The new target is derived from a sum-of-the-parts valuation using updated peer multiples of 12.9x EV/EBITDA for healthcare services and 8.7x for diagnostics, and also incorporates recent acquisitions ahead of the November Q3 results. Despite these positive fundamental revisions, the bank has maintained its 'Hold' rating, signaling a view that the stock's current price already reflects its strong operational performance. A potential upgrade to the investment rating is contingent upon management releasing fresh mid-term targets, which Deutsche Bank is awaiting before reassessing its stance.

Key Decisions for Investors

• Given the 'Hold' rating, investors should consider that while Medicover's fundamentals are strong, the stock may be fairly valued at present, suggesting limited near-term upside.
• The key catalyst for a potential re-rating is the release of new mid-term guidance from management; monitor for this specific event before considering a change in position.
• Scrutinize the upcoming third-quarter results in November for confirmation that the company's strong teens organic growth and operating leverage are tracking in line with the upgraded analyst expectations.